These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 11642689

  • 1. Mechanism of action of and resistance to quinolones.
    Bearden DT, Danziger LH.
    Pharmacotherapy; 2001 Oct; 21(10 Pt 2):224S-232S. PubMed ID: 11642689
    [Abstract] [Full Text] [Related]

  • 2. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
    Ince D, Zhang X, Silver LC, Hooper DC.
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3370-80. PubMed ID: 12384338
    [Abstract] [Full Text] [Related]

  • 3. Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.
    Millanao AR, Mora AY, Villagra NA, Bucarey SA, Hidalgo AA.
    Molecules; 2021 Nov 25; 26(23):. PubMed ID: 34885734
    [Abstract] [Full Text] [Related]

  • 4. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J, Thanassi JA, Thoma CL, Bradbury BJ, Deshpande M, Pucci MJ.
    Antimicrob Agents Chemother; 2007 Jul 25; 51(7):2445-53. PubMed ID: 17502409
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis.
    Onodera Y, Okuda J, Tanaka M, Sato K.
    Antimicrob Agents Chemother; 2002 Jun 25; 46(6):1800-4. PubMed ID: 12019093
    [Abstract] [Full Text] [Related]

  • 6. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?
    Martínez JL, Alonso A, Gómez-Gómez JM, Baquero F.
    J Antimicrob Chemother; 1998 Dec 25; 42(6):683-8. PubMed ID: 10052889
    [No Abstract] [Full Text] [Related]

  • 7. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
    Charrier C, Salisbury AM, Savage VJ, Moyo E, Forward H, Ooi N, Cheung J, Metzger R, McGarry D, Walker R, Cooper IR, Ratcliffe AJ, Stokes NR.
    J Antimicrob Chemother; 2016 Oct 25; 71(10):2831-9. PubMed ID: 27353465
    [Abstract] [Full Text] [Related]

  • 8. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
    Naeem A, Badshah SL, Muska M, Ahmad N, Khan K.
    Molecules; 2016 Mar 28; 21(4):268. PubMed ID: 27043501
    [Abstract] [Full Text] [Related]

  • 9. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N, Mitsuyama J, Furuta Y, Yamada H, Nakata M, Fukuda T, Yamada H, Takahata M, Minami S.
    Jpn J Antibiot; 2002 Aug 28; 55(4):412-39. PubMed ID: 12378871
    [Abstract] [Full Text] [Related]

  • 10. Characterization of mutations in DNA gyrase and topoisomerase IV Involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro.
    Reinhardt AK, Bébéar CM, Kobisch M, Kempf I, Gautier-Bouchardon AV.
    Antimicrob Agents Chemother; 2002 Feb 28; 46(2):590-3. PubMed ID: 11796386
    [Abstract] [Full Text] [Related]

  • 11. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
    Anderson VE, Osheroff N.
    Curr Pharm Des; 2001 Mar 28; 7(5):337-53. PubMed ID: 11254893
    [Abstract] [Full Text] [Related]

  • 12. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J, Hooper DC.
    Antimicrob Agents Chemother; 2005 May 28; 49(5):1949-56. PubMed ID: 15855518
    [Abstract] [Full Text] [Related]

  • 13. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents.
    Mitscher LA.
    Chem Rev; 2005 Feb 28; 105(2):559-92. PubMed ID: 15700957
    [No Abstract] [Full Text] [Related]

  • 14. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
    Ostrer L, Khodursky RF, Johnson JR, Hiasa H, Khodursky A.
    Int J Antimicrob Agents; 2019 Mar 28; 53(3):318-324. PubMed ID: 30582984
    [Abstract] [Full Text] [Related]

  • 15. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
    Hooper DC.
    Clin Infect Dis; 1998 Aug 28; 27 Suppl 1():S54-63. PubMed ID: 9710672
    [Abstract] [Full Text] [Related]

  • 16. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.
    Smith HJ, Nichol KA, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2002 Jun 28; 49(6):893-5. PubMed ID: 12039880
    [No Abstract] [Full Text] [Related]

  • 17. Quinolone resistance mechanisms in pneumococci.
    Eliopoulos GM.
    Clin Infect Dis; 2004 May 15; 38 Suppl 4():S350-6. PubMed ID: 15127369
    [Abstract] [Full Text] [Related]

  • 18. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M, Fukuda H, Kishii R, Hosaka M.
    Antimicrob Agents Chemother; 2001 Dec 15; 45(12):3544-7. PubMed ID: 11709337
    [Abstract] [Full Text] [Related]

  • 19. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
    Oizumi N, Kawabata S, Hirao M, Watanabe K, Okuno S, Fujiwara T, Kikuchi M.
    J Infect Chemother; 2001 Sep 15; 7(3):191-4. PubMed ID: 11810583
    [Abstract] [Full Text] [Related]

  • 20. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.
    Hooper DC, Jacoby GA.
    Cold Spring Harb Perspect Med; 2016 Sep 01; 6(9):. PubMed ID: 27449972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.